Hugo Yamada, MD
Internal Medicine · Lincoln, RINPI 1932196904
Payments from drug & device makers
Across 156 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$416
- Novo Nordisk$263
- Pfizer$243
- Boehringer Ingelheim$234
- AstraZeneca$188
- Sanofi-aventis U.S. LLC$166
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,54799%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 24 | $416 |
| Novo Nordisk | 14 | $263 |
| Pfizer | 23 | $243 |
| Boehringer Ingelheim | 11 | $234 |
| AstraZeneca | 7 | $188 |
| Sanofi-aventis U.S. LLC | 8 | $166 |
| Amgen | 8 | $156 |
| Lilly USA, LLC | 9 | $138 |
| E.r. Squibb & Sons, L.L.C. | 6 | $101 |
| Merck | 5 | $70 |
| Regeneron Healthcare Solutions, Inc. | 4 | $61 |
| GSK | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Amarin Pharma, Inc. | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 8 | $55 |
| Novartis | 3 | $41 |
| Melinta Therapeutics, LLC | 2 | $39 |
| Strongbridge US Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Dexcom, Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Lupin Inc. | 1 | $14 |
How this compares
$2,581 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 349 | $275,911 |
| EliquisApixaban | 349 | $262,027 |
| GlyxambiEmpagliflozin/Linagliptin | 233 | $175,690 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 167 | $174,104 |
| FarxigaDapagliflozin Propanediol | 210 | $143,717 |
| TrulicityDulaglutide | 118 | $123,437 |
| XareltoRivaroxaban | 73 | $78,386 |
| OzempicSemaglutide | 62 | $68,714 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $44,479 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 39 | $35,107 |
| TradjentaLinagliptin | 69 | $34,688 |
| MounjaroTirzepatide | 23 | $23,270 |
| JanuviaSitagliptin Phosphate | 32 | $22,591 |
| RybelsusSemaglutide | 18 | $19,626 |
| Atorvastatin Calcium | 1,648 | $17,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr, Tradjenta, Trijardy Xr | $234 | $542,055724 claims |
| PfizerEliquis | $243 | $262,027349 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $166 | $174,104167 claims |
| AstraZenecaFarxiga, Brilinta | $188 | $150,719224 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $138 | $146,707141 claims |
| Novo NordiskOzempic, Rybelsus | $263 | $88,33980 claims |
| Johnson & JohnsonXarelto | $416 | $78,38673 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $58 | $54,86885 claims |
| MerckJanuvia, Lagevrio (Eua), Janumet Xr | $70 | $36,44664 claims |
| NovartisEntresto | $41 | $10,28011 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $18 | $4,40413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Lincoln
- Frank D'alessandroLincoln$541K
- Christopher SuperczynskiLincoln$9K
- David FriedEast Greenwich$37.2M
- Gregory AllenCranston$12.2M
- Kathleen GordonJohnston$1.1M
- William BeliveauJohnson$962K
- Scott WilsonCumberland$907K
- Aaron SamuelsProvidence$751K
- Andrew HsuProvidence$409K
- Heinrich ElinzanoProvidence$396K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.